Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CXADR


Brief Information

Name:Calcium sensing receptor
Target Synonym:Parathyroid cell calcium-sensing receptor 1,FHH,FIH,HHC,Receptors, Calcium-Sensing,Extracellular calcium-sensing receptor,hCasR,GPRC2A,Calcium Sensing Receptor,Parathyroid Ca(2+)-Sensing Receptor 1,Severe Neonatal Hyperparathyroidism,Calcium-Sensing Receptor,HYPOC1,NSHPT,PCaR1,EIG8,HHC1,CaSR,CAR,Hypocalciuric Hypercalcemia 1
Number of Launched Drugs:6
Number of Drugs in Clinical Trials:5
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
CXR-H5222 Human Human CXADR / CAR Protein, His Tag
ACRO Quality

Synonym Name



Coxsackie virus and adenovirus receptor (CXADR) is also known as CAR, is a type I transmembrane glycoprotein for group B coxsackie viruses and subgroup C adenoviruses, and belongs to the CTX family of the Ig superfamily. CAR is strongly expressed in the developing central nervous system. It functions as a homophilic and also as a heterophilic cell adhesion molecule through its interactions with extracellular matrix glycoproteins such as: fibronectin, agrin, laminin-1 and tenascin-R. Human

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Upacicalcet SK-1403; AJT-240 Approved Ajinomoto Co Inc ウパシタ, Upasita Japan Hyperparathyroidism, Secondary Sanwa Kagaku Kenkyusho Co Ltd 2021-06-23 Hyperparathyroidism, Secondary Details
Parathyroid hormone (Shire) NPSP-795; rhPTH (1-84); rhPTH-1-84; PTH (1-84); SB-423562; PTH 1-84; NPSP-558; SHP-635; SHP-634; ALX-111; 423562; EBP-05; EB-612 Approved Shire Natpara, Preotact, Natpar United States Hypoparathyroidism Nps Pharmaceuticals, Inc 2006-04-24 Osteoporosis; Bone Diseases, Endocrine; Osteoporosis, Postmenopausal; Hypocalcemia; Psoriasis; Hypoparathyroidism; Hyperparathyroidism Details
Cinacalcet Hydrochloride AMG-073.HCl; NPS-1493; AMG-073; KRN-1493 Approved Amgen Inc Parareg, Sensipar, Mimpara, Regpara, 盖平, Sensipar/Mimpara United States Hypercalcemia; Hyperparathyroidism, Secondary Amgen Inc 2004-03-08 Hyperparathyroidism, Secondary; Rejection of renal transplantation; Hypophosphatemia; Edema, Cardiac; Parathyroid Neoplasms; Nephrosis; Kidney Diseases; Hypercalcemia; Hyperparathyroidism, Primary; Prostatic Neoplasms; Osteomalacia; Renal Insufficiency, Chronic; Hyperparathyroidism; Kidney Failure, Chronic; Chronic Kidney Disease-Mineral and Bone Disorder Details
Etelcalcetide Hydrochloride ONO-5163; KAI-4169; AMG-416; KAI-4169-HCl Approved Amgen Inc Parsabiv EU Hyperparathyroidism, Secondary Amgen Europe Bv 2016-11-11 Hyperparathyroidism, Secondary; Edema, Cardiac; Renal Insufficiency, Chronic; Kidney Failure, Chronic Details
Strontium Ranelate S-12911; S-12911-2; FK-481 Approved Laboratoires Servier Osseor, Protos, Protelos, 欧思美 Mainland China Osteoporosis, Postmenopausal Les Laboratoires Servier 2004-09-20 Osteoporosis, Postmenopausal Details
Evocalcet KHK-7580; MT-4580 Approved Mitsubishi Tanabe Pharma Corp Orkedia Japan Hyperparathyroidism, Secondary Kyowa Hakko Kirin Co Ltd 2018-03-23 Hyperparathyroidism, Secondary; Parathyroid Neoplasms; Hyperparathyroidism, Primary; Hyperparathyroidism Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Encaleret sulfate MK-5442; JTT-305; CLTX-305 Phase 3 Clinical Japan Tobacco (Hong Kong) Ltd Osteoporosis; Hypocalcemia; Osteoporosis, Postmenopausal; Hypoparathyroidism Details
LNP-1892 LNP-1892 Phase 2 Clinical Lupin Ltd Hyperparathyroidism Details
DS-9194b DS-9194b Phase 1 Clinical Daiichi Sankyo Co Ltd Osteoporosis Details
OSM-0205 OSM-0205 Phase 1 Clinical Yale University, Osmol Therapeutics Inc Peripheral Nervous System Diseases; Peripheral Nerve Injuries Details
RT-102(Rani) RT-102 Phase 1 Clinical Rani Therapeutics Holdings Inc Osteoporosis Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message